SV2B enhances TFE3‐RCC progression by activating the NF‐κB pathway, which is a crucial pathway that promotes or inhibits tumor progression depending on the cell type.[32, 33] Our study showed that NF‐κB is activated and plays a cancer‐promoting role in TFE3‐RCC. Here, SV2B is linked to renal cell carcinoma.